Argenx announced positive top-line results from its phase 3 trial of Vyvgart in autoimmune myositis, or IIM, with the study meeting its primary endpoint at week 52 in the combined patient population of immune-mediated necrotizing myopathy and dermatomyositis. Shares soared 16% on Aug. 17.
Novel FcRn inhibitor Vyvgart is a pipeline in a product, currently approved in myasthenia gravis and CIDP in the US, but it's being evaluated in multiple additional indications.
Vyvgart’s initial average price in myasthenia gravis of $225,000 per year per patient in the US could fall over time, as international launches progress and as competitors reach the market.
|
Metric
|
ARGX
|
CSL
|
UCB
|
|---|---|---|---|
Price/Earnings (Normalized) | 36.22 | 19.61 | 17.11 |
Price/Book Value | 7.45 | 3.81 | 3.35 |
Price/Sales | 12.54 | 3.56 | 4.65 |
Price/Cash Flow | 41.90 | 15.92 | 16.31 |
|
Metric
|
ARGX
|
CSL
|
UCB
|
|---|---|---|---|
Quick Ratio | 4.52 | 0.88 | 0.82 |
Current Ratio | 5.12 | 2.21 | 1.20 |
Interest Coverage | 411.30 | −8.46 | 27.73 |
|
Metric
|
ARGX
|
CSL
|
UCB
|
|---|---|---|---|
Return on Assets (Normalized) | 22.69% | 8.38% | 13.57% |
Return on Equity (Normalized) | 30.35% | 17.61% | 23.59% |
Return on Invested Capital (Normalized) | 24.38% | 11.10% | 19.03% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|r<@xz# | LOCK|#@$T | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Ns^wxr | LOCK|$%<y | $83B | |||
| Moderna Inc
MRNA
| LOCK|$rK@<y | LOCK|@q | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@tfXC# | LOCK|rcz | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^#%zhd | LOCK|?h#b | $35B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|X%hyl&b | LOCK|#v%K | $27B | |||
| Incyte Corp
INCY
| LOCK|^#D!&R | LOCK|K<h | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|K>bP$$c | LOCK|<g> | $25B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|mkz$R< | LOCK|ZjB | $16B |
United States